Brown M, Awad M, Schmidt C. (2022). An Immunological Argument for One Health. Am J Immunol 18(1): 5-8. Doi: 10.3844/ajisp.2022.5.8.
Schmidt C, Christian L, Smith TA, Tidwell J, Kim D, Tucker HO. (2021). Lipid Rafts Interaction of the ARID3A Transcription Factor with EZRIN and G-Actin Regulates B-Cell Receptor Signaling. Diseases 9(1): 22. Doi: 10.3390/diseases9010022.
Blase CM, Rouault BK, Zoller MB, Luff JV, Lerch EJ, Lauterbach BN, Brown MA, Storsberg J, Schmidt, C. (2019). Individualizing Periods of Commercial Exclusivity to Control Pricing for Drugs and Biologics. Am J Immunol, 15, 19-21. Doi: 10.3844/ajisp.2019.19.21 . [PDF here]
Brown MA, Alshiraihi I, Blase C, Storsberg J, Schmidt C. (2019). Methods for Universal Authentication of Medical Devices. Am J Immunol 15, 1-4. Doi: 10.3844/ajisp.2019.1.4. [PDF here]
Krüger-Genge A, Schmidt C, Storsberg J. (2019). Chocolate cream labels as novel potential biomaterial? About red herrings in the scientific biomaterial scene. J Cell Biotechnol 5(1): 1-2. Doi: 10.3233/JCB-189008. [PDF here]
Krüger-Genge A, Mauger O, Storsberg J, Schmidt C. (2019). Epigenetics—Shedding Light on the Path Ahead for Material Sciences. Diseases 7(2), 43. Doi 10.3390/diseases7020043. [PDF here]
Rykhus RD, Shepard ZV, Young A, Frisby H, Calder KA, Coon CM, Falk JA, McAndrews SR, Turner A, Chang C, Michelsohn J, Petch R, Dieker SM, Markworth BH, Alamo-Perez K, Hosack AJ, Berg JM, Schmidt C, Storsberg J, Brown MA. (2018). Facilitating a More Efficient Commercial Review Process for Pediatric Drugs and Biologics. Diseases 6, 2. Doi: 10.3390/diseases6010002. [PDF here]
Yokaichiya F, Schmidt C, Storsberg J, Vollrath MK, de Araujo DR, Kenta B, Clemens D, Wingert F, Franco MKKD. (2018). Effects of doxorubicin on the structural and morphological characterization of solid lipid nanoparticles (SLN) using small angle neutron scattering (SANS) and small angle X-ray scattering (SAXS). Physica B: Condens Matter 551: 191-196. Doi: 10.1016/j.physb.2017.12.036. [PDF here]
Kim D, Schmidt C, Brown MA, Tucker H. (2017). Competitive Promoter-Associated Matrix Attachment Region Binding of the Arid3a and Cux1 Transcription Factors. Diseases 5: 34. Doi: 10.3390/diseases5040034. [PDF here]
Schmidt C, Storsberg J. (2017). Risk Evaluation Requires an Independent Mind. Diseases 5: 28. Doi: 10.3390/diseases5040028. [PDF here]
Schmidt C, Kim DK, Marthur S, Covarrubias D, Das C, Brown MA, Storsberg J, Tucker HO. (2017) . The Arid3a Transcription Factor Rescues Natural and RAS-V12-Induced Senescence Via a Rb-Dependent Pathway. Am J Immunol 13: 216-233. [PDF here]
Edwards M, Alshiraihi I, Schmidt C, Storsberg J, Brown MA. (2017). Nitric-Oxide-Mediated Chemosensitization: Gene Therapy Versus Exogenous Introduction of NO Donors In: Nitric Oxide (Donor/Induced) in Chemosensitization, edited by Benjamin Bonavida, Volume 1, 1st Edition, pp. 1-14. Academic Press, Cambridge, MA, USA, published: 29th June, 2017.
Katz DL, Storsberg J, Schmidt, C. (2017). Chasing the Fat Demon: Fat Chance, Buddy? Am J Immunol 13: 86-88. [PDF here]
Sel S, Storsberg J, Brown MA, Schmidt C. (2017). Choice Meaning and Context: Two Sides of the Same Coin? Am J Immunol 13: 89-90. [PDF here]
Schmidt C, Geyer M, Bohrisch J, Jentzen V, Gorczyza A, Khalil K, Volkert M, Brown MA, Sel S, Storsberg J. (2017). Functionalization Strategies for Antibodies: Lessons Learned. Am J Immunol 13: 144-154. [PDF here]
Sel S, Brown MA, Storsberg J, Schmidt C. (2016). What You See Is What You Get. Am J Immunol 12: 52-55. Doi : 10.3844/ajisp.2016.52.55. [PDF here]
Schmidt C, Yokaichiya F, Doğangüzel N, Dias Franco MKK, Cavalcanti LP, Brown MA, Alkschbirs MI, de Araujo DR, Kumpugdee-Vollrath M, Storsberg J. (2016). An Abraded Surface of Doxorubicin-LoadedSurfactant-Containing Drug Delivery Systems Effectively Reduces the Survival of Carcinoma Cells. Biomedicines 4: 22. Doi: 10.3390/biomedicines4030022. [PDF here]
Storsberg J, Brown MA, Schmidt C. (2016). Vaccination Against Heart Attack? Am J Immunol 12: 49-51. Doi : 10.3844/ajisp.2016.49.51. [PDF here]
Brown MA, Storsberg J, Schmidt C. (2016). Where the Future is Being Made Today. Am J Immunol 12: 17-19. Doi: 10.3844/ajisp.2016.17.19. [PDF here]
Schmidt C, Fabinyi S, Rehfeldt S, Klöpzig S, Jentzen V, Bohrisch J, Messner A, Storsberg J. (2016). Non-antagonistic influence of Krumeich's intrastromal corneal ring in an experimental tissue culture system. Ophthalmologe 113: 852-860. [PDF here]
Storsberg J, Laughton MW, Geyer M, Kumpugdee-Vollrath M, Schmidt C. (2016). Improving the bioavailability of pharmacologically active substances in pharmaceutical and cosmetic formulations. AJPS 11: 33-34. [PDF here]
Schmidt C, Brown MA. (2015). Relating the Pendulum of Democracy with Oncology Research. J Clin Exp Oncol 4:3. Doi:10.4172/2324-9110.1000e109. [PDF here]
Schmidt C, Brown MA. (2015). The Sins of Omission. J Clin Exp Oncol 4:2. Doi: 10.4172/2324-9110.1000e108. [PDF here]
Brown MA, Schmidt C. (2015). Curbing the Costs of Cancer Treatment. J Can Epi Treat 1(1): 13-14. Doi: 10.24218/jcet.2015.06. [PDF here]
Schmidt C, Storsberg J. (2015). Nanomaterials—Tools, Technology and Methodology of Nanotechnology Based Biomedical Systems for Diagnostics and Therapy. Biomedicines 3: 203-23. [PDF here]
Yokaichiya F, Dias Franco MKK, Rodrigues T, de Araujo DR, Storsberg J, Schmidt C. (2015). Shed a Light in the Darkness: Technology against Cancer. J Can Epi Treat 1(1): 4-5. Doi: 10.24218/jcet.2015.03. [PDF here]
Laughton MW, Storsberg J, Schmidt C. (2015). Where do we stand on Organ Printing? J Can Epi Treat 1(1):2-3. [PDF here]
Storsberg J, Schmidt C. (2015). The Risk Associated with Corneal Transplantation from Donors with Cancer: Worth the Gamble? J Can Epi Treat 1(1): 1. Doi: 10.24218/jcet.2015.01. [PDF here]
Vetter L, Laughton MW, Schmidt C, Storsberg J. (2014). Anti-Ageing Creams, Ingredients and their Effects Against Early Skin Ageing. SOFW J 140: 32-9 & SOFW J (English Edition) 140: 34-9. [PDF here]
Schmidt C, Doğangüzel N, Klöpzig S, Rehfeldt S, Behne S, da Silva R-J, Krause J-P, Kumpugdee-Vollrath M, Storsberg J. (2014). Synthesis of doxorubicin containing drug carriers and their in-vitro performance on HeLa and HCT116 cells. Nanotech Dubai 2013 International Conference Proceeding. [PDF here]. Highlighted in Middle East Health: "Researchers use nanoparticles to selectively kill tumour cells and spare healthy tissue" January-February 2014 issue, p. 78. [PDF here].
Storsberg J, Duncker GIW, Schmidt C, Kobuch K, Meßner A, Sel S. (2013). Künstliche Hornhaut für Ultima-ratio-Patienten. Z prakt. Augenheilkd 34: 107-11. [PDF here]
Storsberg J, Schmidt C, Sel S. (2012). Artifical Cornea (Keratoprosthesis) - A Nanotechnologically Modified Biomaterial To Restore Eye Sight To Ultimo Ratio Patients. LIFS ONLINE 1: 29_08_12. [PDF here].
Fujioka S, Son K, Onda S, Schmidt C, Scrabas GM, Okamoto T, Fujita T, Chiao PJ, Yanaga K. (2012). Desensitization of NFκB for overcoming chemoresistance of pancreatic cancer cells to TNF-α or paclitaxel. Anticancer Res 32: 4813-4821. [PDF here]
Tidwell JA, Schmidt C, Heaton P, Wilson V, Tucker PW. (2011). Characterization of a new ARID family transcription factor (Brightlike/ARID3C) that co-activates Bright/ARID3A-mediated immunoglobulin gene transcription. Mol Immunol 49: 260-72. [PDF here]
Webb CF, Bryant J, Popowski M, Allred L, Kim D, Harriss J, Schmidt C, Miner CA, Rose K, Cheng HL, Griffin C, Tucker PW. (2011). The ARID family transcription factor Bright is required for both hematopoietic stem cell and B lineage development. Mol Cell Biol 31: 1041-53. [PDF here]
Schmidt C, Kim D, Ippolito GC, Naqvi HR, Probst L, Mathur S, Rosas-Acosta G, Wilson VG, Oldham AL, Poenie M, Webb CF, Tucker PW. (2009). Signalling of the BCR is regulated by a lipid rafts-localised transcription factor, Bright. EMBO J 28: 711-24. [PDF here] [Supplementary Material]
Naqvi HR, Mathur S, Covarrubias D, Curcio JA, Schmidt C. (2008). The problem of choice. Mol Cancer 7: 86. [PDF here]
Christian LM, Naqvi HR, Schmidt C, Covarrubias D, Mathur S. (2008). Another challenge for scientists. Mol Cancer 7: 63. [PDF here]
Covarrubias D, Van Emburgh M, Naqvi HR, Schmidt C, Mathur S. (2008). To know or not to know: archiving and the under-appreciated historical value of data. Mol Cancer 7: 18. [PDF here]
Schmidt C. (2007). Book Review of "The Molecular Biology of Cancer" by Stella Pelengaris, Michael Khan (Editors). Mol Cancer 6: 72. [PDF here]
Mathur S, Schmidt C. (2007). An open democracy. Mol Cancer 6: 43. [PDF here]
Brown MA, Zhu L, Schmidt C, Tucker PW. (2007). Hsp90 - from signal transduction to cell transformation. Biochem Biophys Res Commun 363: 241-6. [PDF here]
Mathur S, Schmidt C, Das C, Tucker PW. (2006). Open access and beyond. Mol Cancer 5: 35. [PDF here]
Ippolito GC, Schmidt C, Das C, Tucker PW. (2005). Towards open access. Mol Cancer 4: 20. [PDF here]
Sclabas GM, Uwagawa T, Schmidt C, Hess KR, Evans DB, Abbruzzese JL, Chiao PJ. (2005). Nuclear factor κB activation is a potential target for preventing pancreatic carcinoma by aspirin. Cancer 103: 2485-90. [PDF here]
Sclabas GM, Fujioka S, Schmidt C, Li Z, Frederick WA, Yang W, Yokoi K, Evans DB, Abbruzzese JL, Hess KR, Zhang W, Fidler IJ, Chiao PJ. (2005). Overexpression of tropomysin-related kinase B in metastatic human pancreatic cancer cells. Clin Cancer Res 11: 440-9. [PDF here]
Fujioka S, Schmidt C, Sclabas GM, Li Z, Pelicano H, Peng B, Yao A, Niu J, Zhang W, Evans DB, Abbruzzese JL, Huang P, Chiao PJ. (2004). Stabilization of p53 is a novel mechanism for proapoptotic function of NF-κB. J Biol Chem 279: 27549-27559. [PDF here]
Chiao PJ, Schmidt C. (2004). Open Access gains attention in scholar communication. Mol Cancer 3: 23. [PDF here]
Fujioka S, Niu J, Schmidt C, Sclabas GM, Peng B, Uwagawa T, Li Z, Evans DB, Abbruzzese JL, Chiao PJ. (2004). NF-κB and AP-1 connection: mechanism of NF-κB-dependent regulation of AP-1 activity. Mol Cell Biol 24: 7806-19. [PDF here]
Schmidt C, Peng B, Li Z, Sclabas GM, Fujioka S, Niu J, Schmidt-Supprian M, Evans DB, Abbruzzese JL, Chiao PJ. (2003). Mechanisms of proinflammatory cytokine-induced biphasic NF-κB activation. Mol Cell 12: 1287-300. [PDF here]
Kannan S, Lakku RA, Niranjali D, Jayakumar K, Steven AH, Taralakshmi VV, Chandramohan S, Balakrishnan R, Schmidt C, Halagowder D. (2003). Expression of peanut agglutinin-binding mucin-type glycoprotein in human esophageal squamous cell carcinoma as a marker. Mol Cancer 2: 38. [PDF here]
Deora AB, Luettich K, Schmidt C, Sclabas GM. (2003). First anniversary of Molecular Cancer: achievements and future goals. Mol Cancer 2: 26. [PDF here]
Luettich K, Schmidt C, Sclabas GM. (2003). Frequently asked questions about Molecular Cancer. Mol Cancer 2: 16. [PDF here]
Fujioka S, Sclabas GM, Schmidt C, Niu J, Frederick WA, Dong QG, Abbruzzese JL, Evans DB, Baker C, Chiao PJ. (2003). Inhibition of constitutive NF-κB activity by IκBαM suppresses tumorigenesis. Oncogene 22: 1365-70. [PDF here]
Sclabas GM, Fujioka S, Schmidt C, Evans DB, Chiao PJ. (2003). NF-κB in pancreatic cancer. Int J Gastrointest Cancer 33: 15-26. [PDF here]
Fujioka S, Sclabas GM, Schmidt C, Frederick WA, Dong QG, Abbruzzese JL, Evans DB, Baker C, Chiao PJ. (2003). Function of nuclear factor κB in pancreatic cancer metastasis. Clin Cancer Res 9: 346-54. [PDF here]
Sclabas GM, Fujioka S, Schmidt C, Fan Z, Evans DB, Chiao PJ. (2003). Restoring apoptosis in pancreatic cancer cells by targeting the nuclear factor-κB signaling pathway with the anti-epidermal growth factor antibody IMC-C225. J Gastrointest Surg 7: 37-43. [PDF here]
Pommerenke H, Schmidt C, Dürr F, Nebe B, Lüthen F, Müller P, Rychly J. (2002). The mode of mechanical integrin stressing controls intracellular signaling in osteoblasts. J Bone Miner Res 17: 603-11. [PDF here]
Schmidt C. (2002) Bench and Bedside. Mol Cancer 1: 1. [PDF here]
Dong QG, Sclabas GM, Fujioka S, Schmidt C, Peng B, Wu T, Tsao MS, Evans DB, Abbruzzese JL, McDonnell TJ, Chiao PJ. (2002). The function of multiple IκB : NF-κB complexes in the resistance of cancer cells to Taxol-induced apoptosis. Oncogene 21: 6510-9. [PDF here]
Löhr M, Schmidt C, Ringel J, Kluth M, Müller P, Nizze H, Jesnowski R. (2001). Transforming growth factor-β1 induces desmoplasia in an experimental model of human pancreatic carcinoma. Cancer Res 61: 550-5. [PDF here]
Löhr M, Müller P, Zauner I, Schmidt C, Trautmann B, Thévenod F, Capellá G, Farré A, Liebe S, Jesnowski R. (2001). Immortalized bovine pancreatic duct cells become tumorigenic after transfection with mutant k-ras. Virchows Arch 438: 581-90. [PDF here]
Ibrahim SM, Ringel J, Schmidt C, Ringel B, Müller P, Koczan D, Thiesen HJ, Löhr M. (2001). Pancreatic adenocarcinoma cell lines show variable susceptibility to TRAIL-mediated cell death. Pancreas 23: 72-9. [PDF here]
Ringel J, Jesnowski R, Schmidt C, Ringel J, Köhler HJ, Rychly J, Batra SK, Löhr M. (2001). CD44 in normal human pancreas and pancreatic carcinoma cell lines. Teratog Carcinog Mutagen 21: 97-106. [PDF here]
Ringel J, Rychly J, Nebe B, Schmidt C, Müller P, Ringel J, Emmrich J, Liebe S, Löhr M. (1999). CD44, bFGF and hyaluronan in human pancreatic cancer cell lines. Ann NY Acad Sci 880: 238-42. [PDF here]
Schmidt C, Pommerenke H, Dürr F, Nebe B, Rychly J. (1998). Mechanical stressing of integrin receptors induces enhanced tyrosine phosphorylation of cytoskeletally anchored proteins. J Biol Chem 273: 5081-5. [PDF here]